| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
1 Karmanos Cancer Institute and 2 Department of Immunology and Microbiology, School of Medicine, Wayne State University, and 3 Division of Immunopathology, St. John Hospital and Medical Center, Detroit, Michigan
Requests for reprints: Wei-Zen Wei, Karmanos Cancer Institute, Wayne State University, 110 East Warren Avenue, Detroit, MI 48201. Phone: 313-833-0715 Ext 2360; Fax: 313-831-7518; E-mail: weiw{at}karmanos.org.
When CD4+CD25+ regulatory T cells are depleted or inactivated for the purpose of enhancing antitumor immunity, the risk of autoimmune disease may be significantly elevated because these regulatory T cells control both antitumor immunity and autoimmunity. To evaluate the relative benefit and risk of modulating CD4+CD25+ regulatory T cells, we established a new test system to measure simultaneously the immune reactivity to a tumor-associated antigen, neu, and an unrelated self-antigen, thyroglobulin. BALB/c mice were inoculated with TUBO cells expressing an activated rat neu and treated with anti-CD25 monoclonal antibody to deplete CD25+ cells. The tumors grew, then regressed, and neu-specific antibodies and IFN-
–secreting T cells were induced. The same mice were also exposed to mouse thyroglobulin by chronic i.v. injections. These mice produced thyroglobulin-specific antibody and IFN-–secreting T cells with inflammatory infiltration in the thyroids of some mice. The immune responses to neu or thyroglobulin were greater in mice undergoing TUBO tumor rejection and thyroglobulin injection than in those experiencing either alone. To the best of our knowledge, this is the first experimental system to assess the concurrent induction and possible synergy of immune reactivity to defined tumor and self-antigens following reduction of regulatory T cells. These results illustrate the importance of monitoring immune reactivity to self-antigens during cancer immunotherapy that involves immunomodulating agents, and the pressing need for novel strategies to induce antitumor immunity while minimizing autoimmunity.
This article has been cited by other articles:
|
|
 |
|
  J. B. Jacob, Y.-c. M. Kong, I. Nalbantoglu, D. P. Snower, and W.-Z. Wei Tumor Regression following DNA Vaccination and Regulatory T Cell Depletion in neu Transgenic Mice Leads to an Increased Risk for Autoimmunity J. Immunol., May 1, 2009; 182(9): 5873 - 5881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. H. Wang, G.-H. Chen, Y. Fan, M. Van Antwerp, and J. R. Baker Jr. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Inhibits Experimental Autoimmune Thyroiditis by the Expansion of CD4+CD25+ Regulatory T Cells Endocrinology, April 1, 2009; 150(4): 2000 - 2007. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. Radkevich-Brown, J. Jacob, M. Kershaw, and W.-Z. Wei Genetic Regulation of the Response to Her-2 DNA Vaccination in Human Her-2 Transgenic Mice Cancer Res., January 1, 2009; 69(1): 212 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Whittington, M. P. Piechocki, H. H. Heng, J. B. Jacob, R. F. Jones, J. B. Back, and W.-Z. Wei DNA Vaccination Controls Her-2+ Tumors that Are Refractory to Targeted Therapies Cancer Res., September 15, 2008; 68(18): 7502 - 7511. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sharma, A. L. Dominguez, S. Z. Manrique, F. Cavallo, S. Sakaguchi, and J. Lustgarten Systemic Targeting of CpG-ODN to the Tumor Microenvironment with Anti-neu-CpG Hybrid Molecule and T Regulatory Cell Depletion Induces Memory Responses in BALB-neuT Tolerant Mice Cancer Res., September 15, 2008; 68(18): 7530 - 7540. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Saitoh, N. Abiru, M. Nakahara, and Y. Nagayama CD8+CD122+ T Cells, a Newly Identified Regulatory T Subset, Negatively Regulate Graves' Hyperthyroidism in a Murine Model Endocrinology, December 1, 2007; 148(12): 6040 - 6046. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. McLachlan, Y. Nagayama, P. N. Pichurin, Y. Mizutori, C.-R. Chen, A. Misharin, H. A. Aliesky, and B. Rapoport The Link between Graves' Disease and Hashimoto's Thyroiditis: A Role for Regulatory T Cells Endocrinology, December 1, 2007; 148(12): 5724 - 5733. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. B. Jacob, Y.-c. M. Kong, C. Meroueh, D. P. Snower, C. S. David, Y.-S. Ho, and W.-Z. Wei Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells Cancer Res., July 15, 2007; 67(14): 7020 - 7027. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nair, D. Boczkowski, M. Fassnacht, D. Pisetsky, and E. Gilboa Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity Cancer Res., January 1, 2007; 67(1): 371 - 380. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Ferretti, A. Felici, M. S. Pino, and F. Cognetti Does CTLA4 Influence the Suppressive Effect of CD25+CD4+ Regulatory T Cells? J. Clin. Oncol., December 1, 2006; 24(34): 5469 - 5470. [Full Text] [PDF]
|
|
|
|
|
|
S. Rolla, C. Nicolo, S. Malinarich, M. Orsini, G. Forni, F. Cavallo, and F. Ria Distinct and Non-Overlapping T Cell Receptor Repertoires Expanded by DNA Vaccination in Wild-Type and HER-2 Transgenic BALB/c Mice J. Immunol., December 1, 2006; 177(11): 7626 - 7633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Ambrosino, M. Spadaro, M. Iezzi, C. Curcio, G. Forni, P. Musiani, W.-Z. Wei, and F. Cavallo Immunosurveillance of erbb2 carcinogenesis in transgenic mice is concealed by a dominant regulatory T-cell self-tolerance. Cancer Res., August 1, 2006; 66(15): 7734 - 7740. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Beyer and J. L. Schultze Regulatory T cells in cancer Blood, August 1, 2006; 108(3): 804 - 811. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
